Based on current evidence, all individuals with an SDH‐deficient GIST, regardless of etiology (described below), are at risk for associated tumors such as paragangliomas, renal cell carcinomas, and other SDHx‐related tumors, and should be monitored according to established guidelines [11, 15]. This evidence concerns the gene SDHB and paraganglioma.